Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 7/20 | 0.52 |
| ▸ | PLA2G2A | P14555 | 4/20 | 0.37 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16509432 | 0.90 | PLA2G4A (0.49) | PLA2G4APLA2G2ASMPD1 | |
| SCHEMBL16181565 | 0.78 | CETP (0.42) | PLA2G4A | |
| SCHEMBL15907842 | 0.68 | PLA2G4A (1.00) | PLA2G4A | |
| SCHEMBL21132793 | 0.62 | PLA2G2A (0.50) | PLA2G4APLA2G2A | |
| SCHEMBL18826517 | 0.62 | PLA2G4A (0.44) | PLA2G4APLA2G2A | |
| SCHEMBL16181236 | 0.62 | PLA2G4A (0.44) | PLA2G4APLA2G2ASMPD1 | |
| SCHEMBL24542824 | 0.61 | S1PR1 (0.40) | PLA2G4APLA2G2A | |
| SCHEMBL12313943 | 0.60 | FABP3 (0.41) | PLA2G4APLA2G2ASMPD1 | |
| SCHEMBL19928630 | 0.60 | FABP3 (0.41) | PLA2G4APLA2G2ASMPD1 | |
| SCHEMBL16575579 | 0.60 | PLA2G2A (0.70) | PLA2G4APLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865865-B2 | N-terminally modified tetrapeptide derivatives having a C-terminal arginine mimetic | PHILIPPS-UNIVERSITAT MARBURG (DE) | 2014-10-21 | — | — | US | disclosed |
| US-20110312873-A1 | N-TERMINALLY MODIFIED TETRAPEPTIDE DERIVATIVES HAVING A C-TERMINAL ARGININE MIMETIC | PHILIPPS-UNIVERSITAT MARBURG (DE) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312873-A1 | N-TERMINALLY MODIFIED TETRAPEPTIDE DERIVATIVES HAVING A C-TERMINAL ARGININE MIMETIC | FURIN, IAPP, APP | PLA2G4A 2883/4885PLA2G2A 3388/4885SMPD1 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.